Exploration of Targeted Anti-tumor Therapy

Open Access Original Article

Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study

Garhima Arora ... Samrat Chatterjee

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:208–226

DOI: https://doi.org/10.37349/etat.2021.00042

This article belongs to the special issue Calcium Signaling Apparatus in Cancers

Full Text PDF

4106 123 0

Open Access Editorial

Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?

Carminia Maria Della Corte ... Floriana Morgillo

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:204–207

DOI: https://doi.org/10.37349/etat.2021.00041

This article belongs to the special issue Liquid Biopsy in Thoracic Cancer

Full Text PDF

2346 23 0

Open Access Original Article

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors

Ibrahim H. Kankia ... Yusuf Y. Deeni

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:187–203

DOI: https://doi.org/10.37349/etat.2021.00040

Full Text PDF

2548 58 1

Open Access Review

Gastrointestinal disorders as immune-related adverse events

Daniele Balducci ... Luca Maroni

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174–186

DOI: https://doi.org/10.37349/etat.2021.00039

This article belongs to the special issue Immunotherapy in Cancer Patients

Full Text PDF

3339 36 2

Open Access Review

Liquid biopsy in NSCLC: a new challenge in radiation therapy

Annarita Perillo ... Ida Rosalia Scognamiglio

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:156–173

DOI: https://doi.org/10.37349/etat.2021.00038

This article belongs to the special issue Liquid Biopsy in Thoracic Cancer

Full Text PDF

3328 46 0

Open Access Review

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

Paolo Tarantino ... Giuseppe Curigliano

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:139–155

DOI: https://doi.org/10.37349/etat.2021.00037

Full Text PDF

7273 227 11

Open Access Review

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review

Valeria Cognigni ... Rossana Berardi

Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122–138

DOI: https://doi.org/10.37349/etat.2021.00036

This article belongs to the special issue Immunotherapy in Cancer Patients

Full Text PDF

8082 196 12